4.2 Review

Metastatic Uveal Melanoma Biology and Emerging Treatments

Journal

CANCER JOURNAL
Volume 18, Issue 2, Pages 148-152

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e31824bd256

Keywords

Uveal melanoma; GNAQ; GNA11; BAP1

Categories

Funding

  1. National Cancer Institute [P50CA093459]
  2. National Institutes of Health [K12CA088084]
  3. GlaxoSmithKline
  4. Bristol Myers Squibb

Ask authors/readers for more resources

Uveal melanoma is the most common primary intraocular cancer in adults. Nearly half of primary uveal melanoma tumors metastasize, but there are currently no effective therapies for metastatic uveal melanoma. The recent discovery of mutations that underlie uveal melanoma metastasis, growth, and survival provide a key to the molecular understanding of this disease. Much work is now underway to leverage this knowledge to develop effective therapies. This review summarizes recently discovered molecular features of uveal melanoma and therapies being explored to capitalize on this knowledge.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available